Epigenetic protein families: a new frontier for drug discovery
The DOI matches its Crossref record; 192 of the 194 references it cites were found in a registry or an index.
Abstract
Epigenetic regulation of gene expression is a dynamic and reversible process that establishes normal cellular phenotypes but also contributes to human diseases. At the molecular level, epigenetic regulation involves hierarchical covalent modification of DNA and the proteins that package DNA, such as histones. Here, we review the key protein families that mediate epigenetic signalling through the acetylation and methylation of histones, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-containing proteins and proteins that bind to methylated histones. These protein families are emerging as druggable classes of enzymes and druggable classes of protein-protein interaction domains. In this article, we discuss the known links with disease, basic molecular mechanisms of action and recent progress in the pharmacological modulation of each class of proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They have also been demonstrated to possess greater isoform selectivity profiles, targeting specifically only the class I subgroup of HDACs (6-10, 26, 38, 39).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
In the citing paper
“The benzamides face a more difficult path to the observed binding mode, with two plausible binding trajectories. The ligand could enter via an acetyl release and disposal channel (7, 24, 33, 42) or via the hydrophobic tube, settling into a rearranged foot pocket before forming the zinc complex, which locks the inhibitor in place.”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
SMART, a simple modular architecture research tool: Identification of signaling domains
Schultz, J., Milpetz, F., Bork, P., & Ponting, C. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.5857 · Cited by 3,599
Research works printed but not linked: 1
- Allis, C. D., Jenuwein, T. & Reinberg, D. Epigenetics (Cold Spring Harbor Laboratory Press, New York, 2007).
Cited by
Items 301–400 of 1,001
Inhibition and Mechanism of HDAC8 Revisited
Chen, K., Zhang, X., Wu, Y.-D., & Wiest, O. (2014) · Journal of the American Chemical Society · doi:10.1021/ja501548p · Cited by 61
Li, C., Tu, J., Han, G., Liu, N., & Sheng, C. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113961 · Cited by 65
Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension
Kim, J., Lee, A., Choi, J., Park, Y., Kang, H., Chang, W., Lee, M.-S., & Kim, J. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.45 · Cited by 60
Yao, Y., Liao, C., Li, Z., Wang, Z., Sun, Q., Liu, C., Yang, Y., Tu, Z., & Jiang, S. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.024 · Cited by 61
“Most clinical trial HDACi is pan-HDAC inhibitors, which seem to lack selectivity when assessed in biochemical or cellular assays [15,16].”
BackgroundRevisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer
Giannopoulou, A. F., Velentzas, A. D., Konstantakou, E. G., Avgeris, M., Katarachia, S. A., Papandreou, N. C., Kalavros, N., Mpakou, V., Iconomidou, V. A., Anastasiadou, E., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061291 · Cited by 65
Molecular Pathways: Protein Methyltransferases in Cancer
Copeland, R. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0223 · Cited by 59
Histone Methyltransferase Inhibitors: Novel Epigenetic Agents for Cancer Treatment
Zagni, C., Chiacchio, U., & Rescifina, A. (2012) · Current Medicinal Chemistry · doi:10.2174/092986713804806667 · Cited by 64
Galdeano, C., & Ciulli, A. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0059 · Cited by 59
Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators
Zhan, P., Itoh, Y., Suzuki, T., & Liu, X. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00229 · Cited by 60
Camilleri, E. T., Dudakovic, A., Riester, S. M., Galeano‐Garces, C., Paradise, C. R., Bradley, E. W., McGee‐Lawrence, M. E., Im, H., Karperien, M., Krych, A. J., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003909 · Cited by 59
“Epigenetic signaling mechanisms are both dynamic and reversible, which makes them attractive targets for therapeutic drug discovery (1).”
BackgroundThe Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs
Geurs, S., Clarisse, D., De Bosscher, K., & D’hooghe, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00226 · Cited by 58
Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective
Webb, T., Craigon, C., & Ciulli, A. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128653 · Cited by 57
Functional AdoMet Isosteres Resistant to Classical AdoMet Degradation Pathways
Huber, T. D., Wang, F., Singh, S., Johnson, B. R., Zhang, J., Sunkara, M., Lanen, S. G. V., Morris, A. J., Phillips, G. N., & Thorson, J. S. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00348 · Cited by 60
Yuan, Z., Chen, S., Gao, C., Dai, Q., Zhang, C., Sun, Q., Lin, J., Guo, C., Chen, Y., & Jiang, Y. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.03.027 · Cited by 60
Krone, M. W., Travis, C. R., Lee, G. Y., Eckvahl, H. J., Houk, K. N., & Waters, M. L. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c06568 · Cited by 63
Epigenetic Regulation of Neuroinflammation in Alzheimer’s Disease
Ma, Y., Wang, W., Liu, S., Qiao, X., Xing, Y., Zhou, Q., & Zhang, Z. (2023) · Cells · doi:10.3390/cells13010079 · Cited by 61
“For example, methylation of H3K4, H3K48, and H3K79 is associated with transcriptional activation, while H3K9 and H3K27 methylation causes transcriptional down-regulation [99,100].”
BackgroundEZH 2: an emerging role in melanoma biology and strategies for targeted therapy
Tiffen, J. C., Gallagher, S. J., & Hersey, P. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12280 · Cited by 64
“Indeed fifteen chromatin states were described on the basis of different marks with 9 acetyl and methyl groups (Arrowsmith et al., 2012).”
BackgroundSato, S., Katsushima, K., Shinjo, K., Hatanaka, A., Ohka, F., Suzuki, S., Naiki‐Ito, A., Soga, N., Takahashi, S., & Kondo, Y. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3339 · Cited by 62
Targeting non-bromodomain chromatin readers
Arrowsmith, C. H., & Schapira, M. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0290-2 · Cited by 57
Self-citationOsko, J. D., & Christianson, D. W. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127023 · Cited by 56
Samartzis, E. P., Noske, A., Samartzis, N., Fink, D. A., & Imesch, P. (2013) · Reproductive Sciences · doi:10.1177/1933719113488450 · Cited by 61
“The other classes are class IIa, including HDAC-4, HDAC-5, HDAC-7, and HDAC-9; class IIb, including HDAC-6 and HDAC-10; class III, which comprises the sirtuins SIRT1-SIRT7; and class IV, which includes HDAC-11.(9) A recent study demonstrated that the acetylated histone levels in endometriotic cells were significantly…”
BackgroundOn the Histone Lysine Methyltransferase Activity of Fungal Metabolite Chaetocin
Cherblanc, F., Chapman, K. L., Reid, J., Borg, A. J., Sundriyal, S., Alcázar‐Fuoli, L., Bignell, E., Demetriades, M., Schofield, C. J., DiMaggio, P. A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401063r · Cited by 57
“experiments was purchased from BPS Bioscience; Histone H3 (1-21) Biotinylated Peptides”
Duchenne muscular dystrophy: an updated review of common available therapies
Salmaninejad, A., Valilou, S. F., Bayat, H., Ebadi, N., Daraei, A., Yousefi, M., Nesaei, A., & Mojarrad, M. (2018) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1430694 · Cited by 61
“The developing understanding that numerous of these factors are liable to embarrassment by small molecules has resulted in clinical development of some so-called epigenetic drugs [66].”
Lysine methylation signaling of non-histone proteins in the nucleus
Levy, D. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03142-0 · Cited by 63
Chen, R., Qiu, H., Tong, Y., Liao, F., Hu, X., Qiu, Y.-R., & Liao, Y. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.06.083 · Cited by 56
Is an “Epigenetic Diet” for Migraines Justified? The Case of Folate and DNA Methylation
Fila, M., Chojnacki, C. J., Chojnacki, J., & Błasiak, J. (2019) · Nutrients · doi:10.3390/nu11112763 · Cited by 61
“The histone code, which is a combination of various chemical modifications of histone tails including acetylation, methylation, phosphorylation, ubiquitination, sumoylation, and others, is established post-translationally by the histone-modifying enzymes that form large protein complexes with DNA-binding proteins and…”
BackgroundDrug design targeting active posttranslational modification protein isoforms
Meng, F., Liang, Z. T., Zhao, K., & Luo, C. (2020) · Medicinal Research Reviews · doi:10.1002/med.21774 · Cited by 61
Lai, F., Jin, L., Gallagher, S. J., Mijatov, B., Zhang, X. D., & Hersey, P. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00002-6 · Cited by 59
SETD2 and DNMT3A screen in the Sotos-like syndrome French cohort
Tlemsani, C., Luscan, A., Leulliot, N., Bieth, É., Afenjar, A., Baujat, G., Doco‐Fenzy, M., Goldenberg, A., Lacombe, D., Lambert, L., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103638 · Cited by 60
Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors
Vreese, R. D., & D’hooghe, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.013 · Cited by 58
“Histone deacetylases (HDACs) have been discovered as a class of enzymes which regulate the removal of acetyl groups from lysine residues of histones, consequently playing an important regulatory role in epigenetics [2].”
BackgroundCombination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP
Zucconi, B. E., Makofske, J. L., Meyers, D. J., Hwang, Y., Wu, M., Kuroda, M. I., & Cole, P. A. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00160 · Cited by 61
Perspectives on natural product epigenetic modulators in chemical biology and medicine
Cherblanc, F., Davidson, R. W. M., Fruscia, P. D., Srimongkolpithak, N., & Fuchter, M. J. (2013) · Natural Product Reports · doi:10.1039/c3np20097c · Cited by 67
Massively parallel knock-in engineering of human T cells
Dai, X., Park, J. J.-Y., Du, Y., Na, Z., Lam, S. Z., Chow, R. D.-W., Renauer, P. A., Gu, J., Shan, X., Chu, Z., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01639-x · Cited by 57
Giri, S., & Bader, A. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.011 · Cited by 67
Ma, F., Liu, M., Wang, Z., & Zhang, C. (2015) · Chemical Communications · doi:10.1039/c5cc08797j · Cited by 54
Chemical probes and inhibitors of bromodomains outside the BET family
Moustakim, M., Clark, P. G. K., Hay, D. A., Dixon, D. J., & Brennan, P. E. (2016) · MedChemComm · doi:10.1039/c6md00373g · Cited by 54
Myrianthopoulos, V., Gaboriaud‐Kolar, N., Tallant, C., Hall, M. L., Grigoriou, S., Brownlee, P. M., Fedorov, O., Rogers, C. M., Heidenreich, D. J., Wanior, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00355 · Cited by 55
Bioinformatics Tools for Genome-Wide Epigenetic Research
Angarica, V. E., & del Sol, A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53889-1_25 · Cited by 64
Cheng, G., Wang, Z., Yang, J., Bao, Y., Xu, Q., Zhao, L., & Liu, D. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.12.011 · Cited by 53
“Lysine post-translational modification (PTM), one kind of well-studied epigenetic mechanisms, plays an extensive role in cell signaling, such as phosphorylation, methylation, acetylation and ubiquitination [5].”
BackgroundEpigenetics as a New Frontier in Orthopedic Regenerative Medicine and Oncology
van Wijnen, A. J., & Westendorf, J. J. (2019) · Journal of Orthopaedic Research® · doi:10.1002/jor.24305 · Cited by 55
“current appreciation of chromatin‐related epigenetic mechanisms permits realistic adaptation of epigenetic drugs for short‐term local applications in orthopedic regenerative medicine.(9) The development, maintenance, repair, and functional performance of musculoskeletal tissues require intricate intracellular chemical…”
BackgroundEpigenetics-based therapeutics for myocardial fibrosis
Li, X., Yang, Y., Chen, S., Zhou, J., Li, J., & Cheng, Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119186 · Cited by 57
Gou, P., & Zhang, W. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116130 · Cited by 65
Epigenetic control of gene function in schistosomes: a source of therapeutic targets?
Cabezas‐Cruz, A., Lancelot, J., Caby, S., Oliveira, G., & Pierce, R. J. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00317 · Cited by 56
Chemogenomic Profiling of Endogenous PARK2 Expression Using a Genome-Edited Coincidence Reporter
Hasson, S. A., Fogel, A. I., Wang, C., MacArthur, R., Guha, R., Heman-Ackah, S., Martin, S., Youle, R. J., & Inglese, J. (2015) · ACS Chemical Biology · doi:10.1021/cb5010417 · Cited by 54
Mohammadi, A., Sharifi, A., Pourpaknia, R., Haftcheshmeh, S. M., & Sahebkar, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.05.009 · Cited by 56
Cui, H., Divakaran, A., Pandey, A. K., Johnson, J. A., Zahid, H., Hoell, Z. J., Ellingson, M. O., Shi, K., Aihara, H., Harki, D. A., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202008625 · Cited by 45
ATP-Dependent Chromatin Remodeling Complexes as Novel Targets for Cancer Therapy
Mayes, K., Qiu, Z., Alhazmi, A., & Landry, J. W. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00005-6 · Cited by 65
“In some cases, small molecules targeting these regulators have made it into Phase II clinical trials (Arrowsmith et al., 2012; Dawson et al., 2012; Nebbioso et al., 2012; Plass et al., 2013).”
BackgroundCarlino, L., & Rastelli, G. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00438 · Cited by 53
INO80 is required for oncogenic transcription and tumor growth in non-small cell lung cancer
Zhang, S., Zhou, B., Wang, L., Li, P., Bennett, B. D., Snyder, R., Garantziotis, S., Fargo, D. C., Cox, A. D., Chen, L., et al. (2016) · Oncogene · doi:10.1038/onc.2016.311 · Cited by 56
Xu, D., Gao, Y., Hu, N., Wu, L., & Chen, Q. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050977 · Cited by 53
“HDACs are a family of enzymes that catalyze the removal of acetyl groups from lysine residues in histones and non-histone proteins and they play a key role in the transcriptional regulation of gene expressions [17,18].”
BackgroundJohnstone, A. L., Andrade, N. S., Barbier, E., Khomtchouk, B. B., Rienas, C. A., Lowe, K., Booven, D. J. V., Domi, E., Esanov, R., Vilca, S. J., et al. (2019) · Addiction Biology · doi:10.1111/adb.12816 · Cited by 54
Evanno, E., Godet, J., Piccirilli, N., Guilhot, J., Milin, S., Gombert, J. M., Fouchaq, B., & Roche, J. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0380-0 · Cited by 56
“All these processes can be considered as epigenetic-based therapeutic strategy to treat cancer [10].”
Therapeutic potential of selective histone deacetylase 3 inhibition
Zhang, L., Chen, Y., Jiang, Q., Song, W., & Zhang, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.072 · Cited by 51
Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells
Zwergel, C., Schnekenburger, M., Sarno, F., Battistelli, C., Manara, M. C., Stazi, G., Mazzone, R., Fioravanti, R., Gros, C., Ausseil, F., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0663-8 · Cited by 55
Ibrahim, H. S., Abdelsalam, M., Zeyn, Y., Zessin, M., Mustafa, A.-H. M., Fischer, M. A., Zeyen, P., Sun, P., Bülbül, E. F., Vecchio, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010369 · Cited by 50
Han, S., Uludağ, M. O., Usanmaz, S. E., Ayaloglu-Butun, F., Akçalı, K. C., & Demirel-Yılmaz, E. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3737-x · Cited by 50
“binding proteins and non-coding RNAs, and translation control with microRNAs and RNA binding proteins [29].”
BackgroundStructured Water Molecules in the Binding Site of Bromodomains Can Be Displaced by Cosolvent
Huang, D., Rossini, E., Steiner, S., & Caflisch, A. (2013) · ChemMedChem · doi:10.1002/cmdc.201300156 · Cited by 50
Chromatin Modifications Sequentially Enhance ErbB2 Expression in ErbB2-Positive Breast Cancers
Mungamuri, S. K., Murk, W. K., Grumolato, L., Bernstein, E., & Aaronson, S. A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.009 · Cited by 56
“In view of promising new approaches to target epigenetic aberrations in cancer (Arrowsmith et al., 2012; Delmore et al., 2011; Filippakopoulos et al., 2010; Peltomaki, 2012; Rodriguez-Paredes and Esteller, 2011; Zuber et al., 2011), we tested for local histone modifications near the erbB2 promoter…”
BackgroundInfluentialChemical Inhibitors of Epigenetic Methyllysine Reader Proteins
Milosevich, N., & Hof, F. A. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b01073 · Cited by 58
The Promise of Epigenomic Therapeutics in Pancreatic Cancer
Lomberk, G. A., Iovanna, J., & Urrutia, R. A. (2016) · Epigenomics · doi:10.2217/epi-2015-0016 · Cited by 50
Landscapes of Protein Posttranslational Modifications of African Trypanosoma Parasites
Zhang, N., Jiang, N., Zhang, K., Zheng, L., Zhang, D., Sang, X., Feng, Y., Chen, R., Yang, N., Wang, X., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101074 · Cited by 50
Epigenetics: Recent Advances and Its Role in the Treatment of Alzheimer's Disease
Xiao, X., Liu, X., & Jiao, B. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.538301 · Cited by 54
Emerging role of different DNA methyltransferases in the pathogenesis of cancer
Liu, P., Yang, F., Zhang, L., Hu, Y., Chen, B., Wang, J., Su, L., Wu, M., & Chen, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.958146 · Cited by 60
“Furthermore, this growing body of evidence has demonstrated that histone deacetylases (HDACs) are linked to the initiation and/or maintenance of repression for DNA hypermethylated genes, and studies have revealed that the simultaneous targeting of both DNA methylation and histone deacetylation leads to additive or syn…”
BackgroundEpigenetics: A primer for clinicians
Paluch, B. E., Naqash, A. R., Brumberger, Z. L., Nemeth, M. J., & Griffiths, E. A. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.02.002 · Cited by 58
“SAM is a methyl donor in themethylation of lysine or arginine resides [104]; thus, strategies aimed at interrupting SAM binding may be able to block the activity of histone methyltransferases, analogous to ATP binding pocket of kinase inhibitors [105].”
BackgroundChemical Inhibition of Protein Methyltransferases
Schapira, M. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.07.014 · Cited by 51
Self-citationNatural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes
Maolanon, A. R., Kristensen, H. M. E., Leman, L. J., Ghadiri, M. R., & Olsen, C. A. (2017) · ChemBioChem · doi:10.1002/cbic.201600519 · Cited by 46
Post-translational Modifications of Trypanosoma cruzi Canonical and Variant Histones
Picchi, G. F. A., Zulkievicz, V., Krieger, M. A., Zanchin, N. T., Goldenberg, S., & de Godoy, L. M. F. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00655 · Cited by 49
Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2
Barnash, K. D., The, J., Norris-Drouin, J. L., Cholensky, S. H., Worley, B. M., Li, F., Stuckey, J. I., Brown, P. J., Vedadi, M., Arrowsmith, C. H., et al. (2017) · ACS Combinatorial Science · doi:10.1021/acscombsci.6b00174 · Cited by 52
“of SUZ12(1-739) were cloned into pFastBac HT A (Invitrogen).”
BackgroundMethodSelf-citationYokoyama, M., Chiba, T., Zen, Y., Oshima, M., Kusakabe, Y., Noguchi, Y., Yuki, K., Koide, S., Tara, S., Saraya, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15528 · Cited by 50
“Recently, a number of HKMT inhibitors have been developed as potential therapeutic cancer agents [30].”
BackgroundCitrullination/Methylation Crosstalk on Histone H3 Regulates ER-Target Gene Transcription
Clancy, K. W., Russell, A.-M., Subramanian, V., Nguyen, H., Qian, Y., Campbell, R. M., & Thompson, P. R. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00241 · Cited by 52
Zaware, N., & Zhou, M. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.06.012 · Cited by 49
Drug Discovery and Chemical Biology of Cancer Epigenetics
Ribich, S. A., Harvey, D. M., & Copeland, R. A. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.020 · Cited by 50
Revenga, M. D. L. F., Ibi, D., Cuddy, T., Toneatti, R., Kurita, M., Ijaz, M. K., Miles, M. F., Wolstenholme, J. T., & González‐Maeso, J. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0143-4 · Cited by 52
Cermakova, K., & Hodges, H. C. (2018) · Molecules · doi:10.3390/molecules23081958 · Cited by 48
“This breadth serves as a great research tool to dissect the function of these chromatin-associated factors (see Figure 2 and Table 1) [7].”
BackgroundInfluentialBasciu, A., Malloci, G., Pietrucci, F., Bonvin, A. M. J. J., & Vargiu, A. V. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00730 · Cited by 55
Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer
Anwar, T., Gonzalez, M. E., & Kleer, C. G. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.01.013 · Cited by 51
Erythroleukemia-historical perspectives and recent advances in diagnosis and management
Boddu, P., Benton, C. B., Wang, W., Borthakur, G., Khoury, J. D., & Pemmaraju, N. (2018) · Blood Reviews · doi:10.1016/j.blre.2017.09.002 · Cited by 49
“modification proteins with an ability to ‘read’ the genome and modulate gene expression through transcriptional regulator recruitment to specific genome locations [61].”
Zhao, Y., Bai, L., Liu, L., McEachern, D., Stuckey, J. A., Meagher, J. L., Yang, C., Xu, R., Zhou, B. N., Hu, Y., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00193 · Cited by 48
Discovery of Small-Molecule Antagonists of the H3K9me3 Binding to UHRF1 Tandem Tudor Domain
Senisterra, G. A., Zhu, H. Y. H., Luo, X., Zhang, H., Xun, G., Lu, C., Xiao, W., Hajian, T., Loppnau, P., Chau, I., et al. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218766278 · Cited by 51
Self-citationMiranda‐Gonçalves, V., Lameirinhas, A., Macedo‐Silva, C., Lobo, J., Dias, P. C., Ferreira, V., Henrique, R., & Jerónimo, C. (2020) · Cells · doi:10.3390/cells9041053 · Cited by 55
“Hence, HDACs are responsible for loss of acetylation on N-terminal tails of histone H3 and H4, leading to chromatin condensation by restoring the positive charges of lysine with consequent transcription silencing [21], increasing tumorigenesis and tumor aggressiveness [22].”
BackgroundEpigenetic enzyme mutations as mediators of anti-cancer drug resistance
Chen, S., Zhao, Y., Liu, S., Zhang, J., Assaraf, Y. G., Cui, W., & Wang, L. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100821 · Cited by 49
Recent progress and structural analyses of domain‐selective BET inhibitors
Divakaran, A., Harki, D. A., & Pomerantz, W. C. K. (2023) · Medicinal Research Reviews · doi:10.1002/med.21942 · Cited by 48
“The promising efficacy of these epigenetic drugs motivates the search for new disease applications, drug targets, and improved chemical matter to develop epigenetic therapies.(4) As recognition modules of acetylated lysine (Kac) typically associated with histones and transcription factors, bromodomain‐mediated protein…”
BackgroundGut microbiota and epigenetic inheritance: implications for the development of IBD
Guo, X., Li, J., Xu, J., Zhang, L., Huang, C., Nie, Y., & Zhou, Y. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2490207 · Cited by 54
“48,49 However, our research on diseases caused by epigenetic enzymes or chromatin alterations due to multiple factors, including IBD, is not clear.”
Retinoid receptor signaling and autophagy in acute promyelocytic leukemia
Orfali, N., McKenna, S. L., Cahill, M. R., Gudas, L. J., & Mongan, N. P. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.03.018 · Cited by 49
“binding at target promoters also recruits histone-deacetylases (HDACs), histone lysine methyltransferases (KMTs), and DNA methyltransferases (DNMTs) that together result in repressive conformational chromatin changes, further blocking gene transcription [77,78] (Fig.”
Inhibition of histone binding by supramolecular hosts
Allen, H. F., Daze, K. D., Shimbo, T., Lai, A. Y., Musselman, C. A., Sims, J. K., Wade, P. A., Hof, F. A., & Kutateladze, T. G. (2014) · Biochemical Journal · doi:10.1042/bj20140145 · Cited by 47
Genomic targeting of epigenetic probes using a chemically tailored Cas9 system
Liszczak, G., Brown, Z. Z., Kim, S. H., Oslund, R., David, Y., & Muir, T. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615723114 · Cited by 49
“The activity of chromatin regulatory proteins can be manipulated using both genetic and pharmacologic approaches (6, 7).”
BackgroundLysine acetyltransferase Tip60 is required for hematopoietic stem cell maintenance
Numata, A., Kwok, H. S., Zhou, Q., Li, J., Tirado-Magallanes, R., Angarica, V. E., Hannah, R., Park, J., Wang, C. Q., Krishnan, V., et al. (2020) · Blood · doi:10.1182/blood.2019001279 · Cited by 48
Mouse Models for Mycobacterium tuberculosis Pathogenesis: Show and Do Not Tell
Soldevilla, P., Vilaplana, C., & Cardona, P.-J. (2022) · Pathogens · doi:10.3390/pathogens12010049 · Cited by 57
“One of the groups that has been associated with immunomodulatory properties is the family of sirtuins, especially sirtuin 1 [164].”
BackgroundSmall-molecular modulators of cancer-associated epigenetic mechanisms
Itoh, Y., Suzuki, T., & Miyata, N. (2013) · Molecular BioSystems · doi:10.1039/c3mb25410k · Cited by 44
Tang, M., Shen, H., Jin, Y., Lin, T., Cai, Q., Pinard, M. A., Biswas, S., Tran, Q., Li, G., Shenoy, A. K., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.482349 · Cited by 50
Natural compounds in epigenetics: A current view
Miceli, M., Bontempo, P., Nebbioso, A., & Altucci, L. (2014) · Food and Chemical Toxicology · doi:10.1016/j.fct.2014.08.005 · Cited by 48
“teins with a specific domain, such as, for example, chromo- or Tudor domains (Arrowsmith et al., 2012).”
BackgroundComputational Design of a Time-Dependent Histone Deacetylase 2 Selective Inhibitor
Zhou, J., Li, M., Chen, N., Wang, S., Luo, H.-B., Zhang, Y., & Wu, R. (2015) · ACS Chemical Biology · doi:10.1021/cb500767c · Cited by 45
Reverting p53 activation after recovery of cellular stress to resume with cell cycle progression
Lazo, P. A. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.02.005 · Cited by 47
“inhibition of histone deacetylases [117] can be used as a therapeutic target.”
BackgroundHDAC6 inhibition disrupts maturational progression and meiotic apparatus assembly in mouse oocytes
Li, L., Hu, F., Ying, X., Ge, J., & Wang, Q. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1329067 · Cited by 47
“Epigenetic regulation of gene expression is a dynamic and reversible process that does not involve DNA sequence changes but can be inherited, closely related to cell proliferation, differentiation and apoptosis.(3) The covalent modification of histones”
BackgroundAu, K. S., Findley, T. O., & Northrup, H. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38478 · Cited by 50
3H-pyrazolo[4,3-f]quinoline haspin kinase inhibitors and anticancer properties
Opoku‐Temeng, C., Dayal, N., Sooreshjani, M. A., & Sintim, H. O. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.03.031 · Cited by 46
“The link between epigenetic modifications and cancer development has been established[1, 2].”
BackgroundAnti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors
Wang, B., Chen, X., Gao, J., Su, L., Zhang, L., Xu, H., & Luan, Y. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.07.045 · Cited by 46
Angulo, J. C., Manini, C., Lopez, J. I., Pueyo, A., Colás, B., & Ropero, S. (2021) · Cancers · doi:10.3390/cancers13092071 · Cited by 54
Progress towards the ‘Golden Age’ of biotechnology
Gartland, K. M. A., Bruschi, F., Dündar, M., Gahan, P. B., Magni, M. V., & Akbarova, Y. Y. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2013.05.011 · Cited by 58
“Textmining and comparative analysis studies have identified the role of histone methyltransferases, demethylases, acetylases and deacetylases, particularly of lysine and arginine residues in acting as binding sites for transcription factors and other proteins associated with upregulating or downregulating gene express…”
BackgroundDarwish, S., Ghazy, E., Heimburg, T., Herp, D., Zeyen, P., Salem-Altintas, R., Ridinger, J., Schmidtkunz, K., Robaa, D., Erdmann, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147535 · Cited by 48
Metadata
- Authors
- Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M.
- Affiliations
- University of Toronto (CA)
- University of Oxford (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Arrowsmith, Cheryl H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-04-13
- Volume
- 11
- Issue
- 5
- Pages
- 384-400
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2076333986
- Semantic Scholar
- fd3346db3efdf967ef263b7d902523d5edecb53e
- Cited by
- 1,327
- References
- 194
- Citations by year
- 2026: 29 · 2025: 49 · 2024: 47 · 2023: 47 · 2022: 62 · 2021: 85 · 2020: 103 · 2019: 103 · 2018: 93 · 2017: 126 · 2016: 165 · 2015: 132 · 2014: 115 · 2013: 116 · 2012: 54
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Genome Canada
- Wellcome Trust (1097737)
- Ontario Genomics
- Ontario Genomics Institute
- Canadian Institutes of Health Research (1097737)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- epigenetic regulation, histone acetylation, histone methylation, histone deacetylase, protein methyltransferases, lysine demethylase, bromodomain proteins, epigenetic drug targets, epigenetic drug discovery, cancer, inflammation, neuropsychiatric disorders
- MeSH terms
- Acetylation, Animals, Gene Expression Regulation, Histones, Humans, Methylation, Protein Binding, Proteins, Signal Transduction, Epigenesis, Genetic, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.